KERRI LANNI: Open Payments
NPI 1154373223 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$869 in 35 payments from 12 companies in 2025. Trend: 2023 $807 · 2024 $463 · 2025 $869
Food & beverage: $869
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $187 |
| Gilead Sciences, Inc. | 6 | $139 |
| Ipsen Biopharmaceuticals, Inc | 1 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $92 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $75 |
| Madrigal Pharmaceuticals | 2 | $72 |
| Intercept Pharmaceuticals, Inc. | 2 | $60 |
| Ardelyx, Inc. | 2 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
Products named: IQIRVO, XIFAXAN, REZDIFFRA, SKYRIZI, OCALIVA, CREON, IBSRELA, ENTYVIO.
Industry payments across RI — which companies pay providers there.
